{"id":744983,"date":"2014-05-13T01:15:00","date_gmt":"2014-05-13T01:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/"},"modified":"2023-03-22T00:04:55","modified_gmt":"2023-03-22T04:04:55","slug":"merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/","title":{"rendered":"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that it signed an agreement for Santen Pharmaceutical<br \/>\n      Co., Ltd. (Santen) to purchase Merck\u2019s ophthalmology products, COSOPT<sup>\u00ae<\/sup><br \/>\n      (dorzolamide hydrochloride \u2013 timolol maleate ophthalmic solution),<br \/>\n      COSOPT PF<sup>\u00ae<\/sup> (dorzolamide hydrochloride-timolol maleate<br \/>\n      ophthalmic solution) 2%\/0.5%, TRUSOPT<sup>\u00ae<\/sup> (dorzolamide<br \/>\n      hydrochloride ophthalmic solution) sterile ophthalmic solution 2%,<br \/>\n      TRUSOPT PF<sup>\u00ae<\/sup> (dorzolamide hydrochloride ophthalmic solution)<br \/>\n      preservative-free, TIMOPTIC<sup>\u00ae<\/sup> (timolol maleate ophthalmic<br \/>\n      solution), TIMOPTIC PF\u00ae (timolol maleate preservative free ophthalmic<br \/>\n      solution in unit dose dispenser), TIMOPTIC XE<sup>\u00ae<\/sup> (timolol<br \/>\n      maleate ophthalmic gel forming solution), SAFLUTAN<sup>\u00ae<\/sup><br \/>\n      (tafluprost) and TAPTIQOM<sup>\u00ae<\/sup> (tafluprost-timolol maleate<br \/>\n      ophthalmic solution, in development) in Japan and key markets in Europe<br \/>\n      and Asia Pacific.\n    <\/p>\n<p>\n      \u201cThe decision to divest our ophthalmics business is part of our ongoing<br \/>\n      strategy to sharpen our commercial focus and improve our operational<br \/>\n      effectiveness,\u201d said Jay Galeota, president, Hospital and Specialty<br \/>\n      Care, Merck. \u201cThis transaction provides products that complement<br \/>\n      Santen\u2019s portfolio and is designed to ensure continued access for<br \/>\n      physicians and patients to these medicines around the world.\u201d\n    <\/p>\n<p>\n      Santen will make an upfront payment of approximately $600 million and<br \/>\n      additional payments based on defined sales milestones as needed. The<br \/>\n      annual sales of these ophthalmology products in the markets within the<br \/>\n      scope of the agreement are approximately $400 million. Santen will also<br \/>\n      purchase supply of the ophthalmology products covered by this agreement<br \/>\n      from Merck for a two- to five-year period. The agreement is subject to<br \/>\n      certain closing conditions, including obtaining antitrust clearance in<br \/>\n      Japan and other closing conditions related to specific markets or<br \/>\n      regions. The agreement is expected to close in most markets in a few<br \/>\n      months.\n    <\/p>\n<p>\n      Merck divested its U.S. ophthalmology business to Akorn Pharmaceuticals<br \/>\n      in 2013 and 2014. Merck will continue to sell its ophthalmology products<br \/>\n      in Latin America, Canada, Australia, the Middle East, Africa and other<br \/>\n      markets.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50863915&#038;newsitemid=20140512006812&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=9df29714191f0a2594acd11923e609d6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50863915&#038;newsitemid=20140512006812&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=8dd344c5254397eab5449fcce9223585\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50863915&#038;newsitemid=20140512006812&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=d2be1da8b0bfe7f7e58a5513233ebf67\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50863915&#038;newsitemid=20140512006812&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=ced9ec79479c36bfeee49f2c7da252ab\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50863915&#038;newsitemid=20140512006812&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=6dcebf80898050d2bc3e4180a838914c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>COSOPT<\/b><sup><b>\u00ae<\/b><\/sup><b>, COSOPT PF<\/b><sup><b>\u00ae<\/b><\/sup><b>,<br \/>\n      TRUSOPT<\/b><sup><b>\u00ae<\/b><\/sup><b>, TRUSOPT PF<\/b><sup><b>\u00ae<\/b><\/sup><b>,<br \/>\n      TIMOPTIC<\/b><sup><b>\u00ae<\/b><\/sup><b>, TIMOPTIC PF<\/b><sup><b>\u00ae<\/b><\/sup>, <b>TIMOPTIC<br \/>\n      XE<\/b><sup><b>\u00ae<\/b><\/sup><b>, SAFLUTAN<\/b><sup><b>\u00ae<\/b><\/sup><b> and<br \/>\n      TAPTIQOM<\/b><sup><b>\u00ae<\/b><\/sup><b> are trademarks of Merck, Sharp &#038;<br \/>\n      Dohme Corp., a subsidiary of Merck &#038; Co., Inc., Whitehouse Station, N.J.<br \/>\n      USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140512006812r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lappetito, 267-218-1584<br \/>or<br \/>Mamoru        Ohara, 81-3-6272-1001<br \/>or<br \/>Investor:<br \/>Carol Ferguson,        908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck\u2019s ophthalmology products, COSOPT \u00ae (dorzolamide hydrochloride \u2013 timolol maleate ophthalmic solution), COSOPT PF \u00ae (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%\/0.5%, TRUSOPT \u00ae (dorzolamide hydrochloride ophthalmic solution) sterile ophthalmic solution 2%, TRUSOPT PF \u00ae (dorzolamide hydrochloride ophthalmic solution) preservative-free, TIMOPTIC \u00ae (timolol maleate ophthalmic solution), TIMOPTIC PF\u00ae (timolol maleate preservative free ophthalmic solution in unit dose dispenser), TIMOPTIC XE \u00ae (timolol maleate ophthalmic gel forming solution), SAFLUTAN \u00ae (tafluprost) and TAPTIQOM \u00ae (tafluprost-timolol maleate ophthalmic solution, in development) in Japan and key markets in Europe and Asia Pacific. \u201cThe decision to divest our ophthalmics business is part of our ongoing strategy to sharpen our<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744983","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck\u2019s ophthalmology products, COSOPT \u00ae (dorzolamide hydrochloride \u2013 timolol maleate ophthalmic solution), COSOPT PF \u00ae (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%\/0.5%, TRUSOPT \u00ae (dorzolamide hydrochloride ophthalmic solution) sterile ophthalmic solution 2%, TRUSOPT PF \u00ae (dorzolamide hydrochloride ophthalmic solution) preservative-free, TIMOPTIC \u00ae (timolol maleate ophthalmic solution), TIMOPTIC PF\u00ae (timolol maleate preservative free ophthalmic solution in unit dose dispenser), TIMOPTIC XE \u00ae (timolol maleate ophthalmic gel forming solution), SAFLUTAN \u00ae (tafluprost) and TAPTIQOM \u00ae (tafluprost-timolol maleate ophthalmic solution, in development) in Japan and key markets in Europe and Asia Pacific. \u201cThe decision to divest our ophthalmics business is part of our ongoing strategy to sharpen our\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/\",\"name\":\"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2014-05-13T01:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/","og_locale":"en_US","og_type":"article","og_title":"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck\u2019s ophthalmology products, COSOPT \u00ae (dorzolamide hydrochloride \u2013 timolol maleate ophthalmic solution), COSOPT PF \u00ae (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%\/0.5%, TRUSOPT \u00ae (dorzolamide hydrochloride ophthalmic solution) sterile ophthalmic solution 2%, TRUSOPT PF \u00ae (dorzolamide hydrochloride ophthalmic solution) preservative-free, TIMOPTIC \u00ae (timolol maleate ophthalmic solution), TIMOPTIC PF\u00ae (timolol maleate preservative free ophthalmic solution in unit dose dispenser), TIMOPTIC XE \u00ae (timolol maleate ophthalmic gel forming solution), SAFLUTAN \u00ae (tafluprost) and TAPTIQOM \u00ae (tafluprost-timolol maleate ophthalmic solution, in development) in Japan and key markets in Europe and Asia Pacific. \u201cThe decision to divest our ophthalmics business is part of our ongoing strategy to sharpen our","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:55+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/","name":"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx","datePublished":"2014-05-13T01:15:00+00:00","dateModified":"2023-03-22T04:04:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140512006812r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-signs-sale-agreement-with-santen-for-mercks-ophthalmology-products-in-japan-and-key-markets-in-europe-and-asia-pacific\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Signs Sale Agreement with Santen for Merck\u2019s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ab6b075f-7780-4220-a9de-0b0d78e24741","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744983\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744983"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}